{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:59:21Z","timestamp":1770220761566,"version":"3.49.0"},"reference-count":172,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2011,12,27]],"date-time":"2011-12-27T00:00:00Z","timestamp":1324944000000},"content-version":"vor","delay-in-days":360,"URL":"http:\/\/creativecommons.org\/licenses\/by\/3.0\/"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BioMed Research International"],"published-print":{"date-parts":[[2011,1]]},"abstract":"<jats:p>Gastric cancer (GC) is the fourth most common cancer and the second most frequent cause of cancer\u2010related deaths, accounting for 10.4% of cancer deaths worldwide. Despite the improvements, estimated cure rates for patients with advanced stages remain poor, and in the metastatic setting, chemotherapy is the mainstay of palliative therapy and results in objective response rates (ORRs) of only 20\u201340% and median overall survivals (OS) of 8\u201310 months. Therefore, many investigators believe that the potential for making significant progress lies in understanding and exploiting the molecular biology of these tumors to investigate new therapeutic strategies to combat GC, such as specific immunotherapy. In this paper, we analyze the different approaches used for immune\u2010based (especially dendritic and T cells) therapies to gastric cancer treatment and discuss the results obtained in preclinical models as in clinical trials.<\/jats:p>","DOI":"10.1155\/2011\/437348","type":"journal-article","created":{"date-parts":[[2011,12,27]],"date-time":"2011-12-27T21:00:58Z","timestamp":1325019658000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Novel Immunotherapeutic Strategies of Gastric Cancer Treatment"],"prefix":"10.1155","volume":"2011","author":[{"given":"Amedeo","family":"Amedei","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marisa","family":"Benagiano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"della Bella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Niccolai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mario M.","family":"D\u2032Elios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,12,27]]},"reference":[{"key":"e_1_2_6_1_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1207726"},{"key":"e_1_2_6_2_2","volume-title":"Cancer Medicine","author":"Bruckner H. W.","year":"2003"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055531"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.12.9593"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608153350702"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010187"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199812313392704"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035010"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.114"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.0887"},{"key":"e_1_2_6_11_2","article-title":"Phase II study of PS-341 (bortezomib) with or without irinotecan in patients (pts) with advanced gastric adenocarcinomas (AGA)","volume":"18","author":"Ocean A. J.","year":"2006","journal-title":"Journal of Clinical Oncology"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1517\/14712598.8.4.385"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-009-0693-8"},{"key":"e_1_2_6_14_2","first-page":"390","article-title":"The epidemiology of acquired immunodeficiency syndrome malignancies","volume":"27","author":"Goedert J. J.","year":"2000","journal-title":"Seminars in Oncology"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1053\/ajkd.2002.29926"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.3109\/02841869009090048"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020177"},{"key":"e_1_2_6_18_2","first-page":"4296","article-title":"Natural T cell immunity against cancer","volume":"9","author":"Nagorsen D.","year":"2003","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0603-669"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1038\/nri1806"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.183.1.283"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002810000053"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm1039"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31205"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(00)00542-5"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1091-255X(03)00076-3"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1006\/jsre.2001.6158"},{"key":"e_1_2_6_28_2","first-page":"3394","article-title":"Dendritic cells pulsed with HER-2\/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer","volume":"8","author":"Kono K.","year":"2002","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_29_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200317293"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.1101\/gad.897601"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22377"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.171.6.2970"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.309.65.1"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.1038\/nbt1262"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.10.6047"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.imlet.2010.08.008"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2008.243"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2011.04410.x"},{"key":"e_1_2_6_39_2","first-page":"410","article-title":"GM-CSF gene-modified dendritic cell vaccine enhances antitumor immunity in vitro","volume":"32","author":"He S. B.","year":"2010","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.050588297"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970615)79:12<2320::AID-CNCR5>3.0.CO;2-P"},{"key":"e_1_2_6_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2005.10.011"},{"key":"e_1_2_6_43_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.155.6.1823"},{"key":"e_1_2_6_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19950901)76:5<824::AID-CNCR2820760517>3.0.CO;2-N"},{"key":"e_1_2_6_45_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<797::AID-CNCR25>3.0.CO;2-M"},{"key":"e_1_2_6_46_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4073"},{"key":"e_1_2_6_47_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.7.2105"},{"key":"e_1_2_6_48_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19971001)80:7<1198::AID-CNCR3>3.0.CO;2-H"},{"key":"e_1_2_6_49_2","first-page":"1678","article-title":"Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-\u03b3 induction is associated with clinical response","volume":"6","author":"Gollob J. A.","year":"2000","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_50_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.12.119"},{"key":"e_1_2_6_51_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-0121"},{"key":"e_1_2_6_52_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0410"},{"key":"e_1_2_6_53_2","doi-asserted-by":"publisher","DOI":"10.1080\/1042819031000110973"},{"key":"e_1_2_6_54_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2004.08.004"},{"key":"e_1_2_6_55_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-1087-3"},{"key":"e_1_2_6_56_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1571"},{"key":"e_1_2_6_57_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1860"},{"key":"e_1_2_6_58_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0265"},{"key":"e_1_2_6_59_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002620050617"},{"key":"e_1_2_6_60_2","first-page":"1873","article-title":"Anti-CD16\/CD30 bispecific antibody treatment for Hodgkin\u2032s disease: role of infusion schedule and costimulation with cytokines","volume":"7","author":"Hartmann F.","year":"2001","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_61_2","doi-asserted-by":"publisher","DOI":"10.1186\/1756-9966-29-134"},{"key":"e_1_2_6_62_2","first-page":"909","article-title":"Further evidence for prognostic significance of epidermal growth factor receptor gene amplification in patients with esophageal squamous cell carcinoma","volume":"2","author":"Kitagawa Y.","year":"1996","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_63_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602625"},{"key":"e_1_2_6_64_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.gassur.2004.01.006"},{"key":"e_1_2_6_65_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.21.9170"},{"key":"e_1_2_6_66_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.14.7116"},{"key":"e_1_2_6_67_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0805019"},{"key":"e_1_2_6_68_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.16.1327"},{"key":"e_1_2_6_69_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22370"},{"key":"e_1_2_6_70_2","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1913"},{"key":"e_1_2_6_71_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033025"},{"key":"e_1_2_6_72_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa053422"},{"key":"e_1_2_6_73_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2006.24.18_suppl.4064"},{"key":"e_1_2_6_74_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.07.2325"},{"key":"e_1_2_6_75_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.31.9715"},{"key":"e_1_2_6_76_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6606093"},{"key":"e_1_2_6_77_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.15_suppl.4557"},{"key":"e_1_2_6_78_2","unstructured":"MaH. RyanT. andNewmanE. Neoadjuvant therapy of gastric cancer with irinotecan cisplatin and cetuximab followed by surgical resection and adjuvant chemoradiation 58 Proceedings of Graphics Interface American Society of Clinical Oncology (ASCO \u203209) 2009."},{"key":"e_1_2_6_79_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.02.147"},{"key":"e_1_2_6_80_2","unstructured":"KuG. BainsM. RizkN.et al. Phase II trial of pre-operative cisplatin\/irinotecan and radiotherapy for locally advanced esophageal cancer: PET scan after induction therapy may identify early treatment failure 9 Proceedings of Graphics Interface American Society of Clinical Oncology (ASCO \u203207) 2007."},{"key":"e_1_2_6_81_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq591"},{"key":"e_1_2_6_82_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129139"},{"key":"e_1_2_6_83_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1076514"},{"key":"e_1_2_6_84_2","first-page":"4766","article-title":"Regulatory CD4+CD25+ T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer","volume":"61","author":"Woo E. Y.","year":"2001","journal-title":"Cancer Research"},{"key":"e_1_2_6_85_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI31446"},{"key":"e_1_2_6_86_2","unstructured":"Gutenberg-Universitat MainzJ. EbertsD. FathoM. LennerzV.et al. Melanoma-associated Mhc Class I associated oligopeptides and the uses thereof WO\/2007\/025760 2007."},{"key":"e_1_2_6_87_2","unstructured":"PharmaceuticalsA. Cytotoxic T Lymphocyte-stimulation peptides for prevention treatment and diagnosis of melanoma WO\/2001\/032193 2001."},{"key":"e_1_2_6_88_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.242600099"},{"key":"e_1_2_6_89_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12272-010-1111-7"},{"key":"e_1_2_6_90_2","doi-asserted-by":"publisher","DOI":"10.7150\/jca.2.363"},{"key":"e_1_2_6_91_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19970317)70:6<631::AID-IJC1>3.0.CO;2-W"},{"key":"e_1_2_6_92_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0215(19981005)78:2<202::AID-IJC14>3.0.CO;2-C"},{"key":"e_1_2_6_93_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v8.i6.1009"},{"key":"e_1_2_6_94_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2008.05753.x"},{"key":"e_1_2_6_95_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200309000-00003"},{"key":"e_1_2_6_96_2","first-page":"2237","article-title":"Treatment of advanced gastric cancer by chemotherapy combined with autologous cytokine-induced killer cells","volume":"26","author":"Jiang J.","year":"2006","journal-title":"Anticancer Research"},{"key":"e_1_2_6_97_2","first-page":"3997","article-title":"Prospective study of chemotherapy in combination with cytokine-induced killer cells in patients suffering from advanced non-small cell lung cancer","volume":"28","author":"Wu C.","year":"2008","journal-title":"Anticancer Research"},{"key":"e_1_2_6_98_2","doi-asserted-by":"publisher","DOI":"10.1089\/cbr.2005.20.173"},{"key":"e_1_2_6_99_2","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.145.5.1615"},{"key":"e_1_2_6_100_2","first-page":"1767","article-title":"Prognostic significance of adoptive immunotherapy with tumor-associated lymphocytes in patients with advanced gastric cancer: a randomized trial","volume":"8","author":"Kono K.","year":"2002","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_101_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/86.15.1159"},{"key":"e_1_2_6_102_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200307000-00005"},{"key":"e_1_2_6_103_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2007.10.016"},{"key":"e_1_2_6_104_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.1129139"},{"key":"e_1_2_6_105_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1535-6108(03)00113-2"},{"key":"e_1_2_6_106_2","unstructured":"MolmedS. P. A. TraversariC. andBordignonC. Antigen transduced T cells used as a delivery system for antigens WO\/2004\/035768 2004."},{"key":"e_1_2_6_107_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5319.1719"},{"key":"e_1_2_6_108_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.18.10437"},{"key":"e_1_2_6_109_2","doi-asserted-by":"publisher","DOI":"10.1080\/14653240310001497"},{"key":"e_1_2_6_110_2","unstructured":"Yeda Research and Development Co LTD EshharZ. SchindlerD. WaksT. andGrossG. Chimeric receptor genes and cells transformed therewith WO\/1993\/019163 1993."},{"key":"e_1_2_6_111_2","unstructured":"Fred Hutchinson Cancer Research Center GreenbergP. D. andNelsonB. H. Chimeric cytokine receptors in lymphocytes WO\/1994\/022914 1994."},{"key":"e_1_2_6_112_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20021288"},{"key":"e_1_2_6_113_2","unstructured":"Sierra Sciences Inc. AndrewsW. H. FosterC. A. FraserS. andMohammadpourH. Methods and compositions for modulating telomerase reverse transcriptase (Tert) expression WO\/2002\/016658 2002."},{"key":"e_1_2_6_114_2","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.bi.57.070188.002303"},{"key":"e_1_2_6_115_2","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.12-5-610"},{"key":"e_1_2_6_116_2","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dji242"},{"key":"e_1_2_6_117_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940801)74:3<795::AID-CNCR2820740303>3.0.CO;2-I"},{"key":"e_1_2_6_118_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.4900"},{"key":"e_1_2_6_119_2","first-page":"1311","article-title":"Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model","volume":"1","author":"Goldstein N. I.","year":"1995","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_120_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.7447"},{"key":"e_1_2_6_121_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl459"},{"key":"e_1_2_6_122_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605521"},{"key":"e_1_2_6_123_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdp069"},{"key":"e_1_2_6_124_2","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2009.27.15_suppl.4567"},{"key":"e_1_2_6_125_2","unstructured":"ZhangX. XuJ. andShenL. A phase II study of cetuximab with cisplatin and capecitabine as first-line treatment in advanced gastric cancer 39 Proceedings of Graphics Interface American Society of Clinical Oncology (ASCO \u203209) 2009."},{"key":"e_1_2_6_126_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605319"},{"key":"e_1_2_6_127_2","first-page":"2901","article-title":"Biweekly oxaliplatin and irinotecan chemotherapy in advanced gastric cancer. A first-line multicenter phase II trial of the arbeitsgemeinschaft medikamentoese tumortherapie (AGMT)","volume":"28","author":"Woell E.","year":"2008","journal-title":"Anticancer Research"},{"key":"e_1_2_6_128_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181e77a92"},{"key":"e_1_2_6_129_2","doi-asserted-by":"crossref","unstructured":"KuG. ShahM. andTangL. Cetuximab (C225) plus irinotecan\/cisplatin (CPT\/ CDDP) for CPT\/CDDP-refractory esophageal cancer 54 Proceedings of the Graphics Interface American Society of Clinical Oncology (ASCO \u203208) 2008.","DOI":"10.1200\/jco.2008.26.15_suppl.15580"},{"key":"e_1_2_6_130_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605522"},{"key":"e_1_2_6_131_2","unstructured":"Sch\u00f8nnemannK. BjerregaardJ. andJensenH. Biweekly cetuximab and irinotecan as second-line therapy to patients with platinium-resistant gastroesophageal cancer 73 Proceedings of the Graphics Interface American Society of Clinical Oncology (GI ASCO \u203209) 2009."},{"key":"e_1_2_6_132_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.05.114"},{"key":"e_1_2_6_133_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604622"},{"key":"e_1_2_6_134_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.1620"},{"key":"e_1_2_6_135_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2003.09.098"},{"key":"e_1_2_6_136_2","doi-asserted-by":"publisher","DOI":"10.1002\/jcp.20007"},{"key":"e_1_2_6_137_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.2910540209"},{"key":"e_1_2_6_138_2","doi-asserted-by":"publisher","DOI":"10.1081\/CNV-100103852"},{"key":"e_1_2_6_139_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0046-8177(00)80195-1"},{"key":"e_1_2_6_140_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043186"},{"key":"e_1_2_6_141_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052306"},{"key":"e_1_2_6_142_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa052122"},{"key":"e_1_2_6_143_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60028-2"},{"key":"e_1_2_6_144_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1999.17.9.2639"},{"key":"e_1_2_6_145_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.3.719"},{"key":"e_1_2_6_146_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200103153441101"},{"key":"e_1_2_6_147_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0502-459"},{"key":"e_1_2_6_148_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.5.1215"},{"key":"e_1_2_6_149_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.08.076"},{"key":"e_1_2_6_150_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61121-X"},{"key":"e_1_2_6_151_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.09.015"},{"key":"e_1_2_6_152_2","doi-asserted-by":"publisher","DOI":"10.1210\/er.18.1.4"},{"key":"e_1_2_6_153_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19970115)79:2<206::AID-CNCR2>3.0.CO;2-I"},{"key":"e_1_2_6_154_2","first-page":"2195","article-title":"Significance of vessel count and vascular endothelial growth factor in human esophageal carcinomas","volume":"4","author":"Kitadai Y.","year":"1998","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_155_2","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20070"},{"key":"e_1_2_6_156_2","first-page":"1161","article-title":"Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus","volume":"6","author":"Shih C. H.","year":"2000","journal-title":"Clinical Cancer Research"},{"key":"e_1_2_6_157_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1010-7940(02)00044-1"},{"key":"e_1_2_6_158_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600129"},{"key":"e_1_2_6_159_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19960301)77:5<858::AID-CNCR8>3.0.CO;2-A"},{"key":"e_1_2_6_160_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3835(99)00426-7"},{"key":"e_1_2_6_161_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032691"},{"key":"e_1_2_6_162_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061884"},{"key":"e_1_2_6_163_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa072113"},{"key":"e_1_2_6_164_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm0901-987"},{"key":"e_1_2_6_165_2","doi-asserted-by":"publisher","DOI":"10.1038\/nm988"},{"key":"e_1_2_6_166_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.81.908"},{"key":"e_1_2_6_167_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.0770"},{"key":"e_1_2_6_168_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn658"},{"key":"e_1_2_6_169_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq065"},{"key":"e_1_2_6_170_2","unstructured":"EnzingerP. FidiasP. andMeyerhardtJ. Phase II study of bevacizumab and docetaxel in metastatic esophageal and gastric cancer 68 Proceedings of the Graphics Interface American Society of Clinical Oncology (ASCO \u203206) 2006."},{"key":"e_1_2_6_171_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02993858"},{"key":"e_1_2_6_172_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1014476602804"}],"container-title":["BioMed Research International"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/downloads.hindawi.com\/journals\/bmri\/2011\/437348.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/downloads.hindawi.com\/journals\/bmri\/2011\/437348.xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1155\/2011\/437348","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T10:33:01Z","timestamp":1720089181000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1155\/2011\/437348"}},"subtitle":[],"editor":[{"given":"Walter J.","family":"Storkus","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,1]]},"references-count":172,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2011,1]]}},"alternative-id":["10.1155\/2011\/437348"],"URL":"https:\/\/doi.org\/10.1155\/2011\/437348","archive":["Portico"],"relation":{},"ISSN":["2314-6133","2314-6141"],"issn-type":[{"value":"2314-6133","type":"print"},{"value":"2314-6141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1]]},"assertion":[{"value":"2011-08-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-09-26","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2011-12-27","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"437348"}}